UK-based STORM Therapeutics Ltd’s corporate strategy has received a significant boost with the publication in Nature showing the biotech’s first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy for treating acute myeloid leukemia as well as solid tumours, clearing the way for human clinical trials in early 2022.
STORM’s METTL3 Inhibitor Effective Against AML
Plans Global Clinical RNA Epigenetic Drug Program in early 2022
Emerging Company Profile: STORM Therapeutics publishes data in Nature showing its first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy against AML.
